Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...
Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a previously announced debt-facility, are expected to pr ...
TipRanks on MSN
MoonLake Reports Promising Phase 2 Trial Results
MoonLake Immunotherapeutics ( ($MLTX) ) has shared an announcement. On November 5, 2025, MoonLake Immunotherapeutics announced promising results ...
MoonLake intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, to fund the research and development of sonelokimab and for ...
The incidence of OA is rapidly rising among middle-aged adults worldwide and is projected to climb further through 2050.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback